
Quarterly report 2024-Q3
added 11-07-2024
Avinger Revenue 2011-2026 | AVGR
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Avinger
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.65 M | 8.27 M | 10.1 M | 8.76 M | 9.13 M | 7.92 M | 9.93 M | 19.2 M | 10.7 M | 11.2 M | 13 M | 8.56 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 19.2 M | 7.65 M | 10.4 M |
Quarterly Revenue Avinger
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.65 M | 1.85 M | 1.86 M | - | 1.82 M | 2.04 M | 1.89 M | - | 2.25 M | 2.13 M | 1.89 M | - | 2.37 M | 2.8 M | 2.56 M | - | 2.3 M | 1.47 M | 2.26 M | - | 2.41 M | 2.32 M | 1.84 M | - | 2.02 M | 2.06 M | 1.81 M | - | 2.07 M | 2.46 M | 3.49 M | 4.68 M | 5.32 M | 4.68 M | 4.54 M | 2.86 M | 2.72 M | 3.05 M | 2.09 M | 3.07 M | 2.63 M | 3.39 M | 2.12 M | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 5.32 M | 1.47 M | 2.58 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Acutus Medical
AFIB
|
7.16 M | - | -26.83 % | $ 2.62 M | ||
|
Alphatec Holdings
ATEC
|
764 M | $ 13.94 | -0.71 % | $ 2.09 B | ||
|
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | ||
|
ClearPoint Neuro
CLPT
|
31.4 M | $ 14.09 | -7.06 % | $ 381 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | ||
|
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | ||
|
AxoGen
AXGN
|
225 M | $ 31.87 | 2.07 % | $ 1.47 B | ||
|
Cognyte Software Ltd.
CGNT
|
443 M | $ 7.0 | 5.74 % | $ 503 M | ||
|
EDAP TMS S.A.
EDAP
|
44.1 M | $ 4.38 | -4.58 % | $ 163 M | ||
|
Axonics Modulation Technologies
AXNX
|
274 M | - | - | $ 3.31 B | ||
|
Electromed
ELMD
|
64 M | $ 24.18 | 1.09 % | $ 204 M | ||
|
Aziyo Biologics
AZYO
|
24.7 M | - | 1.37 % | $ 20.5 M | ||
|
Apyx Medical Corporation
APYX
|
52.3 M | $ 3.49 | 2.05 % | $ 121 M | ||
|
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | ||
|
Bio-Rad Laboratories
BIO
|
2.57 B | $ 275.33 | 2.19 % | $ 7.77 B | ||
|
BIOLASE
BIOL
|
49.2 M | - | -13.19 % | $ 166 K | ||
|
Bruker Corporation
BRKR
|
3.37 B | $ 40.88 | 2.48 % | $ 6.09 K | ||
|
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | ||
|
Boston Scientific Corporation
BSX
|
20.1 B | $ 75.65 | 2.97 % | $ 112 B | ||
|
InMode Ltd.
INMD
|
358 M | $ 14.0 | 0.29 % | $ 905 M | ||
|
IRIDEX Corporation
IRIX
|
51.9 M | $ 1.47 | -2.0 % | $ 23.7 M | ||
|
IRadimed Corporation
IRMD
|
73.2 M | $ 102.4 | 1.89 % | $ 1.3 B | ||
|
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | ||
|
CONMED Corporation
CNMD
|
1.37 B | $ 45.89 | -0.18 % | $ 1.42 B | ||
|
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
LivaNova PLC
LIVN
|
1.39 B | $ 71.26 | 1.38 % | $ 3.89 B | ||
|
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M | ||
|
Cutera
CUTR
|
49.5 M | - | -10.19 % | $ 1.99 M | ||
|
Medtronic PLC
MDT
|
33.5 B | $ 97.22 | 0.58 % | $ 125 B | ||
|
Delcath Systems
DCTH
|
37.2 M | $ 9.11 | -10.77 % | $ 260 M | ||
|
Nano-X Imaging Ltd.
NNOX
|
1.3 M | $ 2.48 | 1.02 % | $ 146 M | ||
|
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | ||
|
Dynatronics Corporation
DYNT
|
27.4 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
37.2 M | - | - | $ 10.2 M | ||
|
Second Sight Medical Products
EYES
|
1 K | - | -0.97 % | $ 54.4 M | ||
|
Establishment Labs Holdings
ESTA
|
166 M | $ 77.41 | -1.12 % | $ 2.18 B | ||
|
Insulet Corporation
PODD
|
2.71 B | $ 251.74 | 1.46 % | $ 17.7 B | ||
|
Quanterix Corporation
QTRX
|
122 M | $ 6.7 | 6.52 % | $ 252 M | ||
|
GBS
GBS
|
3.05 M | - | -0.57 % | $ 7.12 M | ||
|
FONAR Corporation
FONR
|
97.6 M | $ 18.53 | -0.3 % | $ 121 M | ||
|
Sintx Technologies
SINT
|
2.63 M | $ 2.89 | -1.87 % | $ 10.8 M | ||
|
MiMedx Group
MDXG
|
419 M | $ 4.97 | -5.78 % | $ 735 M |